TheraRadar
Data updated: Jun 28, 2026

SANCTURA (trospium chloride) · AbbVie

Urology Approved 2004-05-28

SANCTURA is FDA-approved to treat 4 conditions (same as TROSPIUM CHLORIDE).

1
Indication
--
Phase 3 Trials
22
Years on Market

Details

Status
Discontinued
First Approved
2004-05-28
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: TROSPIUM CHLORIDE

SANCTURA Approval History

2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
9 FDA actions from 2004 to 2012
Jul 2012 SUPPL
Label · Labeling
Sep 2011 SUPPL
Label · Labeling
Jan 2011 SUPPL
Label · Labeling

What SANCTURA Treats

4 indications

SANCTURA is approved for 4 conditions since its original approval in 2004. These indications span multiple therapeutic areas including oncology, immunology, and more.

Same approved indications as TROSPIUM CHLORIDE (same active ingredient).

Source: FDA Label
📋

Clinical Trial Registry

7 trials
Trial Sponsor ID Phase Status Title
NCT07063342 CN012-0043 U1111-1321-3511 Ph 1 recruiting A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, and to Explore the Effect of Food After Multiple Doses of Selected Prototypes in Healthy Adult Participants
NCT01166438 ABC results posted PFDN 17 2U01HD041249, 2U10HD041250 Ph 3 completed Anticholinergic vs. Botox Comparison Study
NCT02831231 KAR-001 Ph 1 completed Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
NCT01922115 ACE results posted 13-1352 Ph 4 completed The Effect of Anticholinergics on Cognitive Function in the Elderly
NCT01178827 results posted MA-SXR-09-005 Ph 4 completed Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial
NCT00863551 results posted MA-SXR-09-001 SMART Trial Ph 4 completed Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial
NCT01089751 results posted GMA-SXR-09-004 Ph 4 completed Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

SANCTURA FDA Label Details

Indications & Usage

FDA Label (PDF)

SANCTURA is FDA-approved to treat 4 conditions — same approved indications as TROSPIUM CHLORIDE.

Track SANCTURA with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.